Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells

@article{OliverasFerraros2010EvolutionOT,
  title={Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells},
  author={Cristina Oliveras-Ferraros and Anna Massaguer Vall-llovera and Dolors Carrion Salip and Alejandro V{\'a}zquez-Mart{\'i}n and S{\'i}lvia Cuf{\'i} and Bernardo Queralt and Bego{\~n}a Mart{\'i}n-Castillo and Joan Brunet and R. de Llorens and Javier A. Men{\'e}ndez},
  journal={Investigational New Drugs},
  year={2010},
  volume={30},
  pages={846-852}
}
Molecular mechanisms other than activating KRAS mutations should underlie the occurrence of weaker versus stronger responses to cetuximab (CTX) in EGFR-dependent carcinomas with either an intact KRAS signaling or in which KRAS mutations do not predict CTX efficacy. We hypothesized that KRAS wild-type (WT) tumor cell-line models chronically adapted to grow… CONTINUE READING